TY - JOUR

T1 - Healthcare resource utilization in patients with myeloproliferative neoplasms

T2 - A Danish nationwide matched cohort study

AU - Christensen, Sarah Friis

AU - Svingel, Lise Skovgaard

AU - Kjaersgaard, Anders

AU - Stenling, Anna

AU - Darvalics, Bianka

AU - Paulsson, Bjorn

AU - Andersen, Christen Lykkegaard

AU - Christiansen, Christian Fynbo

AU - Stentoft, Jesper

AU - Starklint, Jorn

AU - Severinsen, Marianne Tang

AU - Clausen, Mette Borg

AU - Hilsoe, Morten Hagemann

AU - Hasselbalch, Hans Carl

AU - Frederiksen, Henrik

AU - Mikkelsen, Ellen Margrethe

AU - Bak, Marie

PY - 2022

Y1 - 2022

N2 - Few studies have assessed healthcare resource utilization (HRU) in patients with Philadelphia-negative myeloproliferative neoplasms (MPN) using a matched cohort design. Further, no detailed assessment of HRU in the years preceding an MPN diagnosis exists. We conducted a registry-based nationwide Danish cohort study, including patients with essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN diagnosed between January 2010 and December 2016. HRU data were summarized annually from 2 years before MPN diagnosis until emigration, death, or end of study (December 2017). We included 3342 MPN patients and 32 737 comparisons without an MPN diagnosis, matched on sex, age, region of residence, and level of education. During the study period, the difference in HRU (rate ratio) between patients and matched comparisons ranged from 1.0 to 1.5 for general practitioner contacts, 0.9 to 2.2 for hospitalizations, 0.9 to 3.8 for inpatient days, 1.0 to 4.0 for outpatient visits, 1.3 to 2.1 for emergency department visits, and 1.0 to 4.1 for treatments/examinations. In conclusion, MPN patients had overall higher HRU than the matched comparisons throughout the follow-up period (maximum 8 years). Further, MPN patients had substantially increased HRU in both the primary and secondary healthcare sector in the 2 years preceding the diagnosis.

AB - Few studies have assessed healthcare resource utilization (HRU) in patients with Philadelphia-negative myeloproliferative neoplasms (MPN) using a matched cohort design. Further, no detailed assessment of HRU in the years preceding an MPN diagnosis exists. We conducted a registry-based nationwide Danish cohort study, including patients with essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN diagnosed between January 2010 and December 2016. HRU data were summarized annually from 2 years before MPN diagnosis until emigration, death, or end of study (December 2017). We included 3342 MPN patients and 32 737 comparisons without an MPN diagnosis, matched on sex, age, region of residence, and level of education. During the study period, the difference in HRU (rate ratio) between patients and matched comparisons ranged from 1.0 to 1.5 for general practitioner contacts, 0.9 to 2.2 for hospitalizations, 0.9 to 3.8 for inpatient days, 1.0 to 4.0 for outpatient visits, 1.3 to 2.1 for emergency department visits, and 1.0 to 4.1 for treatments/examinations. In conclusion, MPN patients had overall higher HRU than the matched comparisons throughout the follow-up period (maximum 8 years). Further, MPN patients had substantially increased HRU in both the primary and secondary healthcare sector in the 2 years preceding the diagnosis.

KW - ambulatory care

KW - case-control studies

KW - early diagnosis

KW - epidemiology

KW - general practice

KW - health resources

KW - healthcare costs

KW - hospitalization

KW - myeloproliferative disorder

KW - registries

KW - QUALITY-OF-LIFE

KW - ESSENTIAL THROMBOCYTHEMIA

KW - MYELOFIBROSIS

KW - EPIDEMIOLOGY

KW - EXPECTANCY

KW - SURVIVAL

KW - DISEASE

KW - TRENDS

KW - IMPACT

KW - RISK

U2 - 10.1111/ejh.13841

DO - 10.1111/ejh.13841

M3 - Journal article

C2 - 35900040

VL - 109

SP - 526

EP - 541

JO - Scandinavian Journal of Haematology

JF - Scandinavian Journal of Haematology

SN - 0902-4441

IS - 5

ER -